Patel, M. R., Montero, A. J., Spira, A. I., Bashir, B., Richardson, D. L., Costa, R. L., Thamake, S., Trone, D., LoRusso, P. (2026). A phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as monotherapy and in combination for patients with advanced solid tumors, including hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) and cyclin E1 (CCNE1)–amplified solid tumors: Updated safety and efficacy results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1094